These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 24997232)
21. No acceleration of UV-induced skin carcinogenesis from evenly spread dietary intake of cyclosporine in contrast to oral bolus dosages. Voskamp P; Bodmann CA; Koehl GE; Tensen CP; Bavinck JN; Willemze R; Geissler EK; de Gruijl FR Transplantation; 2013 Nov; 96(10):871-6. PubMed ID: 23958926 [TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical dust exposure at pharmacies using automatic dispensing machines: a preliminary study. Fent KW; Durgam S; Mueller C J Occup Environ Hyg; 2014; 11(11):695-705. PubMed ID: 24824046 [TBL] [Abstract][Full Text] [Related]
23. Site-specific immunosuppression using a new formulation of topical cyclosporine A with polyethylene glycol-8 glyceryl caprylate/caprate. Tran HS; Malli D; Chrzanowski FA; Puc MM; Matthews MS; Hewitt CW J Surg Res; 1999 May; 83(2):136-40. PubMed ID: 10329107 [TBL] [Abstract][Full Text] [Related]
24. Comparison of long-term impact of immunosuppressants at therapeutic doses on hepatic function and histological changes in unilateral nephrectomized rats. Chen Y; Lin H; Zhang Z; Lin Y; Lu Y; Yuan R; Li M; Nie P; Chen L; Qiu J; Chen L; Xu B; Lin W; Xu J; Du H; Liang J; Zhang Z Exp Toxicol Pathol; 2014 Dec; 66(9-10):423-8. PubMed ID: 25081300 [TBL] [Abstract][Full Text] [Related]
25. Efficacy of a new pulmonary cyclosporine a powder formulation for prevention of transplant rejection in rats. Zijlstra GS; Wolting J; Prop J; Petersen AH; Hinrichs WL; Uges DR; Kerstjens HA; van der Bij W; Frijlink HW J Heart Lung Transplant; 2009 May; 28(5):486-92. PubMed ID: 19416778 [TBL] [Abstract][Full Text] [Related]
26. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Euvrard S; Ulrich C; Lefrancois N Dermatol Surg; 2004 Apr; 30(4 Pt 2):628-33. PubMed ID: 15061847 [TBL] [Abstract][Full Text] [Related]
27. Overview of a 10-year experience on methods and compositions for inducing site-specific immunosuppression with topical immunosuppressants. Hewitt CW; Black KS Transplant Proc; 1996 Apr; 28(2):922-3. PubMed ID: 8623464 [TBL] [Abstract][Full Text] [Related]
28. Interactions in free radicals processes between cyclosporine A and sodium fluoride. Srednicka D; Długosz A Acta Pol Pharm; 2007; 64(6):503-8. PubMed ID: 18323243 [TBL] [Abstract][Full Text] [Related]
29. Renal carcinogenicity of trichloroethylene: update, mode of action, and fundamentals for occupational standard setting. Harth V; Brüning T; Bolt HM Rev Environ Health; 2005; 20(2):103-18. PubMed ID: 16121833 [TBL] [Abstract][Full Text] [Related]
30. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
31. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose. Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449 [TBL] [Abstract][Full Text] [Related]
32. Cyclosporine trough concentrations in predicting allograft rejection and renal toxicity up to 12 months after renal transplantation. Min DI; Perry PJ; Chen HY; Hunsicker LG Pharmacotherapy; 1998; 18(2):282-7. PubMed ID: 9545147 [TBL] [Abstract][Full Text] [Related]
33. Bioavailability of therapeutic proteins by inhalation--worker safety aspects. Pfister T; Dolan D; Bercu J; Gould J; Wang B; Bechter R; Barle EL; Pfannkuch F; Flueckiger A Ann Occup Hyg; 2014 Aug; 58(7):899-911. PubMed ID: 24958792 [TBL] [Abstract][Full Text] [Related]
34. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. Dösch AO; Ehlermann P; Koch A; Remppis A; Katus HA; Dengler TJ Clin Ther; 2006 Jun; 28(6):893-905. PubMed ID: 16860172 [TBL] [Abstract][Full Text] [Related]
35. Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. Carrier M; White M; Pellerin M; Pelletier GB; Pelletier LC Can J Cardiol; 1997 May; 13(5):469-73. PubMed ID: 9179085 [TBL] [Abstract][Full Text] [Related]
36. Time-dependent changes in cyclosporine exposure: implications for achieving target concentrations. Felipe CR; Silva HT; Machado PG; Garcia R; Moreira SR; Pestana JO Transpl Int; 2003 Jul; 16(7):494-503. PubMed ID: 12677364 [TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413 [TBL] [Abstract][Full Text] [Related]
39. Development of a health risk-based surface contamination cleanup standard for occupational exposure to beryllium. Damian P Toxicol Mech Methods; 2011 Feb; 21(2):97-102. PubMed ID: 20649413 [TBL] [Abstract][Full Text] [Related]
40. Molecular effects of cyclosporine and oncogenesis: a new model. André N; Roquelaure B; Conrath J Med Hypotheses; 2004; 63(4):647-52. PubMed ID: 15325009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]